Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens

项目摘要 全身性癌症治疗已经改变了许多癌症患者的面貌， 都是有毒的，而且通常以复杂的组合和方案给予。2011年，我们开始建造 www.example.com网站作为血液学和肿瘤学医疗保健的免费开放资源 专业人士HemOnc.org 指导方针，现在是同类资源中最大的。在2020年，有超过250，000个独特的 来自181个国家的访问者和> 1，000，000的浏览量。用户主要分布在临床医生之间 和药剂师，学员和有经验的从业人员都在使用。平移 研究人员还利用该网站作为领域知识的来源。从2017年开始，我们 规范了www.example.com上大部分内容的结构，使其能够转换为 一个结构化的词汇表，HemOnc。截至2021年1月，HemOnc包含83，879个概念 跨越30个概念类，以及跨越45种关系类型的223，039种关系。显式 HemOnc与RxNorm、CanMED、SNOMED-CT、OncoTree和NCI之间存在映射 同义词词典一些组织和项目积极利用或正在评估HemOnc， 包括AACR项目GENIE，ITCR资助的DeepPhe项目， 癌症联盟和cBioPortal。除了保持内容的稳定增长， 在过去的九年里，我们的目标是加强www.example.com网站， HemOnc本体通过以下五个具体目标：1）呈现交互式排名方案 网站上的图表; 2）允许对方案、研究和 作者与一个互动的方案浏览器; 3）增长和完善HemOnc本体; 4）建立 最重要的抗癌治疗方案的结构化摘要和叙述性概要， 包括确定在代表性不足的人群中专门评价的方案; 5） 培育强大的用户社区。这项工作将由一个有成就的团队进行， 临床医生和翻译研究人员。

Project Summary Systemic cancer treatments have transformed the landscape for many patients with cancer, yet are toxic and often given in complicated combinations and protocols. In 2011, we began to build the HemOnc.org website as a free and open resource for hematology and oncology healthcare professionals. HemOnc.org contains granular information on anti-cancer drugs, regimens, and guidelines, and is now the largest resource of its kind. In 2020, there were >250,000 unique visitors and >1,000,000 pageviews from 181 countries. Users are primarily split between clinicians and pharmacists, with utilization by trainees as well as experienced practitioners. Translational researchers also utilize the site as a source of domain knowledge. Beginning in 2017, we formalized the structure of much of the content on HemOnc.org, enabling its transformation into a structured vocabulary, HemOnc. As of January 2021, HemOnc comprises 83,879 concepts across 30 concept classes, and 223,039 relationships across 45 relationship types. Explicit mappings exist between HemOnc and RxNorm, CanMED, SNOMED-CT, OncoTree, and the NCI Thesaurus. Several organizations and projects actively utilize or are evaluating HemOnc, including AACR Project GENIE, the ITCR-funded DeepPhe project, the Variant Interpretation for Cancer Consortium, and cBioPortal. In addition to maintaining the steady growth in content that has taken place over the past nine years, we aim to enhance the HemOnc.org website and HemOnc ontology through the following five specific aims: 1) present interactive ranked regimen graphs on the website; 2) allow for dynamic temporal exploration of regimens, studies, and authors with an interactive Regimen Browser; 3) grow and refine the HemOnc ontology; 4) build structured summaries and narrative synopses for the most important anticancer regimens, including identification of regimens specifically evaluated in underrepresented populations; 5) cultivate a robust user community. This work will be undertaken by an accomplished team of clinicians and translational researchers.